Eli Lilly and Company
HealthcareNYSE:LLY · New York Stock Exchange
-$15.59 today
Vol 1.14M · Avg 3.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$72.2B of revenue converted into $25.3B of net income for the selected period. Gross margin is 83.5% and net margin is 35.0%, showing how much revenue survives after costs and taxes. EPS is $28.15, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.2B +44.7% | $45.0B +32.0% | $34.1B +19.6% | $28.5B +0.8% | $28.3B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $10.6B +25.5% | $8.4B +18.9% | $7.1B +6.8% | $6.6B -9.3% | $7.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $54.6B +49.1% | $36.6B +35.4% | $27.0B +23.4% | $21.9B +4.3% | $21.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 83.8% +2.5pp | 81.3% +2.1pp | 79.2% +2.5pp | 76.8% +2.6pp | 74.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.3B +21.4% | $11.0B +18.0% | $9.3B +29.5% | $7.2B +3.8% | $6.9B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $11.1B +36.4% | $8.1B +17.2% | $6.9B +14.4% | $6.1B -1.2% | $6.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $24.9B +30.3% | $19.1B +17.6% | $16.3B +22.6% | $13.3B +1.4% | $13.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.6B -11.5% | $1.8B +15.7% | $1.5B +0.3% | $1.5B -1.6% | $1.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | $27.9B +83.5% | $15.2B +77.7% | $8.6B -1.1% | $8.7B +7.7% | $8.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 42.9% +9.1pp | 33.8% +8.7pp | 25.1% -5.2pp | 30.3% +1.9pp | 28.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $29.7B +69.7% | $17.5B +62.2% | $10.8B +24.7% | $8.7B +9.1% | $7.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 45.6% +6.7pp | 38.9% +7.2pp | 31.6% +1.3pp | 30.3% +2.3pp | 28.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $153.3M -12.5% | $175.2M +0.9% | $173.6M +176.4% | $62.8M +147.2% | $25.4M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $795.3M +1.9% | $780.6M +60.7% | $485.9M +46.5% | $331.6M -2.4% | $339.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.0B +17.8% | -$4.8B -13.9% | -$4.2B -129.2% | -$1.8B -3.9% | -$1.8B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $25.7B +102.9% | $12.7B +93.5% | $6.6B -3.7% | $6.8B +10.6% | $6.2B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 39.5% +11.3pp | 28.2% +8.9pp | 19.2% -4.6pp | 23.8% +2.1pp | 21.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.1B +143.6% | $2.1B +59.1% | $1.3B +134.0% | $561.6M -2.1% | $573.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $20.6B +94.9% | $10.6B +102.1% | $5.2B -16.1% | $6.2B +11.9% | $5.6B | $4.9B | $4.8B | $4.7B |
| Net Margin | 31.7% +8.2pp | 23.5% +8.2pp | 15.4% -6.5pp | 21.9% +2.2pp | 19.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $23 +95.6% | $12 +101.7% | $6 -11.3% | $7 +12.3% | $6 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $23 +96.0% | $12 +101.9% | $6 -11.7% | $7 +12.3% | $6 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $898.0M -0.3% | $900.6M +0.1% | $899.4M -5.3% | $950.2M -0.4% | $953.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $898.0M -0.7% | $904.1M +0.1% | $903.3M -4.9% | $950.2M -0.4% | $953.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$577.78B
AbbVie Inc.
NYSE:ABBV
$401.49B
Merck & Co., Inc.
NYSE:MRK
$296.44B
Novartis AG
NYSE:NVS
$292.83B
AstraZeneca PLC
NYSE:AZN
$278.87B
Novo Nordisk A/S
NYSE:NVO
$196.37B
Amgen Inc.
NASDAQ:AMGN
$191.29B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.55B
Pfizer Inc.
NYSE:PFE
$149.31B
Sanofi
NASDAQ:SNY
$106.51B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LLY generate?
Eli Lilly and Company (LLY) reported $65.18B of revenue in fiscal 2025.
Is LLY profitable?
Eli Lilly and Company (LLY) reported $20.64B of net income, with a net margin of 31.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.